ILIT: Follow-up of Rhinitis Quality of Life

NCT05037955 | Completed

• 1 other identifier: 2020-02369
• Study Type: observational
• Target: 162
• Locations: 1 country
• Sites: 1

Brief Summary

Re-evaluation of patients treated with intralymphatic immunotherapy (ILIT) in terms of quality of life and therapeutic efficacy and comparison with subcutaneous immunotherapy (SCIT) 15 years post immunotherapy

Conditions

Allergic Rhinitis Due to Grass Pollen

Outcome Measures

Primary Outcomes (1)

• Rhinoconjunctivitis quality of life

  The standardised scoring of the outcomes "activities", "sleep", "non-nose/eye symptoms", "practical problems", "nasal symptoms", "eye symptoms", and "emotional" are entered in the form names "Rhinoconjunctivitis quality of life questionnaire with standardised activities (RQLQ)". The scoring is from 0 ("not troubled" or "none of the time") to 6 ("extremely troubled" or "all of the time").

  February 2021 through June 2021

Study Arms (3)

ILIT from trial NCT00470457

Patients who received ILIT in the original trial in 2005

SCIT from trial NCT00470457

Patients who received SCIT in the original trial in 2005

SCIT outpatient control

Patients who visited the allergy unit at the University Hospital Zurich and completed SCIT in the last 5 years

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Male and female patients with past or current hay fever due to grass pollen sensitisation. The patients received immunotherapy (SCIT or ILIT) in the NCT00470457 trials from 2005. A control group of patients received and completed SCIT as standard treatment of their hay fever at the Allergy Unit of the University Hospital Zurich during the last five years.

You may qualify if:

• Receiving ILIT or SCIT treatment at the USZ.
• Indication: hay fever (type I sensitisation to grass pollen)
• Adult male and female patients
• Written/digital informed consent of the participating person
• Complete return of both questionnaires

You may not qualify if:

• Discontinuation of immunotherapy
• Incomplete data set
• Pathological barrier (e.g. dementia)
• Language barrier (not understanding the German language)

Sponsors & Collaborators

• University of Zurich: lead

Study Sites (1)

University Hospital Zurich

Zurich, 8091, Switzerland

Location

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor, PhD

Study Record Dates

• First Submitted: August 31, 2021
• First Posted: September 8, 2021
• Study Start: February 1, 2021
• Primary Completion: July 1, 2021
• Study Completion: February 1, 2022
• Last Updated: March 23, 2022

Record last verified: 2022-03

Data Sharing

• IPD Sharing: Will not share

Locations

CH (1)